SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ablynx Reports Excellent Interim Results From Phase I/II Study With Its Anti-IL-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients